{"id":"W3214477505","doi":"10.1182/blood-2021-152225","title":"TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"","keywords":"Rituximab; CD20; Refractory (planetary science); Lymphoma; Medicine; Hodgkin lymphoma; Internal medicine; Cancer research; Oncology; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009969439,0.0007405381,0.001023367,0.0003225029,0.0002927634,0.0007750959,0.0005661627,0.0007312013,0.003017495],"category_scores_gemma":[0.0006554786,0.0002732643,0.001312491,0.0003247753,0.0003745372,0.0007503276,0.0002345123,0.002070391,0.0008418458],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004753585,"about_ca_system_score_gemma":0.0005838748,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004132864,"about_ca_topic_score_gemma":0.001401168,"domain_scores_codex":[0.9997594,0.0001094523,0.00002992991,0.00003102321,0.00003529405,0.00003498584],"domain_scores_gemma":[0.9996425,0.00008524453,0.00009366764,0.0000302517,0.00003290578,0.0001153963],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3800035,0.05620234,0.01633683,0.0043693,0.005815489,0.0008772191,0.0006574705,0.003143753,0.06486886,0.0004546931,0.009706648,0.457564],"study_design_scores_gemma":[0.2950162,0.6059904,0.04354439,0.000388918,0.004901327,0.002511122,0.0003874878,0.003268466,0.02278443,0.0005432789,0.0205787,0.00008533827],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9754797,0.01678259,0.0009145146,0.001021978,0.0001642221,0.0009722915,0.001509876,0.0001127155,0.003042289],"genre_scores_gemma":[0.9839318,0.00877749,0.001227047,0.001273802,0.0001880511,0.0006229736,0.002066408,0.00001975199,0.001892684],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003017495,"threshold_uncertainty_score":0.01009446,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00996564159610825,"score_gpt":0.2315626598768594,"score_spread":0.2215970182807512,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}